ByHeart baby formula’s nationwide recall exposes alarming regulatory failures that put American infants at risk, with 15 babies hospitalized across 12 states in a botulism outbreak that raises serious questions about FDA oversight of our nation’s food supply.
Story Snapshot
- ByHeart recalled all baby formula products nationwide after 15 infants hospitalized with botulism in 12 states since August 2025
- FDA investigation reveals ByHeart represents disproportionate number of sick babies despite holding only 1% of formula market share
- Company expanded recall despite claiming no unopened products tested positive for contamination
- Parents urged to immediately dispose of all ByHeart formula products as federal investigation continues
Nationwide Recall Expands as Cases Mount
ByHeart expanded its voluntary recall from two specific lots to all products nationwide on November 11, 2025, after FDA officials informed company leaders of two additional infant botulism cases.
The recall affects ByHeart Whole Nutrition Infant Formula and Anywhere Pack pouches sold at major retailers including Target, Walmart, Albertsons and Whole Foods. Company cofounders Mia Funt and Ron Belldegrun acknowledged “too many unanswered questions” remain about the outbreak’s cause.
Disproportionate Impact Raises Red Flags
FDA data reveals a troubling pattern in the outbreak investigation. Among 84 infant botulism cases detected since August, 36 babies consumed infant formula, with more than one-third receiving ByHeart products.
This represents a disproportionate impact considering ByHeart holds an estimated 1% of the U.S. infant formula market.
The company distributes approximately 200,000 cans monthly through online sales and major retail chains, making the concentration of cases particularly concerning for parents nationwide.
Testing Discrepancies Complicate Investigation
ByHeart maintains that no unopened products have tested positive for Clostridium botulinum spores or toxins, despite California health officials confirming contamination in an opened can fed to a sick infant.
The company committed to testing every batch with independent third-party laboratories and granted FDA inspectors unrestricted access to facilities in Iowa and Oregon. This testing contradiction highlights potential gaps in quality control protocols that American families depend on for infant safety.
Critical Health Risks Demand Immediate Action
Infant botulism poses severe health risks to babies under one year old, whose immature gut systems cannot fight the bacterial toxin. Symptoms include constipation, poor feeding, drooping eyelids, weak muscle tone, and breathing difficulties requiring immediate medical intervention.
The sole treatment, BabyBIG medication, requires IV administration and hospitalization. Parents possessing ByHeart products should immediately discontinue use and dispose of all formula while seeking alternative feeding options for their infants.
